QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) announces it has entered into a definitive agreement to fully acquire Parse Biosciences, a leading provider of scalable, instrument-free solutions for single-cell research. The acquisition will significantly expand QIAGEN’s Sample technologies portfolio into the fast-growing single-cell sequencing market with highly scalable chemistry designed to power research involving up to millions and billions of cells. Parse’s scalable chemistry is also expected to accelerate growth in the QIAGEN Digital Insights (QDI) bioinformatics business, enabling customers to generate, process and interpret AI-driven single-cell data more efficiently and at much greater scale, from the first sample to actionable insights.
Read the full article: QIAGEN to Acquire Parse Biosciences, Expanding Its Sample Technologies Portfolio into Highly Scalable Single-Cell Solutions //
Source: https://www.businesswire.com/news/home/20251104446487/en/QIAGEN-to-acquire-Parse-Biosciences-expanding-its-Sample-technologies-portfolio-into-highly-scalable-single-cell-solutions